Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2 Positive Metastatic Gastric Cancer

Source :: Business Wire. May 7, 2020
Publication Year :: 2020
Abstract: * Submission based on pivotal phase 2 DESTINY-Gastric01 and phase 1 trial data * Trastuzumab deruxtecan to receive expedited review by Japan MHLW based on SAKIGAKE designation for second potential [...]

Subjects :: Daiichi Sankyo Inc.
Daiichi Sankyo Company Ltd.
Stomach cancer -- Drug therapy
Cancer -- Drug therapy
Pharmaceutical industry
Biological products
Trastuzumab
Cancer metastasis -- Drug therapy
Antibodies
Respiratory system agents
Antineoplastic agents
Health
Destiny
Business
Business, international
Enhertu (Medication)

Tools